beta-L-aspartyl-hydrazine: antileukemic; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 97532 |
| SCHEMBL ID | 24667461 |
| MeSH ID | M0056386 |
| Synonym |
|---|
| 152546-74-2 |
| ai3-52058 |
| beta-l-aspartyl-hydrazine |
| l-aspartic acid hydrazide |
| l-aspartic acid, 4-hydrazide |
| nsc 130683 |
| AKOS006340037 |
| DTXSID80934536 |
| 4-hydrazinylidenehomoserine |
| SCHEMBL24667461 |
| n4-amino-l-asparagine |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||